Sjögreen-Gleisner K, Dewaraja Y K, Chiesa C, Tennvall J, Lindén O, Strand S E, Ljungberg M
Department of Medical Radiation Physics, Lund University, Lund, Sweden.
Q J Nucl Med Mol Imaging. 2011 Apr;55(2):126-54.
Radioimmunotherapy involves the use of radiolabeled monoclonal antibodies (MAbs) to treat malignancy. The therapeutic effect is determined by the radiopharmaceutical, the radiation absorbed dose and previous treatments. There are currently two approved radiopharmaceuticals for the treatment of B-cell lymphoma - the (90)Y-labeled ibritumomab and the (131)I-labeled tositumomab. Both are directed against CD20, albeit not against the same epitope. This paper summarizes current results of dose-responses for normal tissues and tumours of [(131)I]tositumomab and [(90)Y]ibritumomab tiuxetan, discusses them in the context of dosimetry methods used and highlights the assumptions being made in the different dosimetry methodologies. Moreover, we wish to point at the possibility of performing low-cost therapy bremsstrahlung imaging for [(90)Y]ibritumomab tiuxetan to confirm biodistribution, and possibly also for dosimetric calculations.
放射免疫疗法涉及使用放射性标记的单克隆抗体（MAbs）来治疗恶性肿瘤。治疗效果取决于放射性药物、辐射吸收剂量和先前的治疗。目前有两种已获批用于治疗B细胞淋巴瘤的放射性药物——（90）Y标记的伊布替尼单抗和（131）I标记的托西莫单抗。两者均针对CD20，尽管针对的不是同一表位。本文总结了[（131）I]托西莫单抗和[（90）Y]替伊莫单抗的正常组织和肿瘤剂量反应的当前结果，在所用剂量测定方法的背景下对其进行了讨论，并强调了不同剂量测定方法中所做的假设。此外，我们希望指出，有可能对[（90）Y]替伊莫单抗进行低成本的治疗性轫致辐射成像，以确认生物分布，甚至可能用于剂量计算。
